{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"We define a tolerability success as a patient completing the second course of therapy without experiencing a grade 4 or 5 non-hematologic toxicity","groups":[{"description":"All eligible patients received the second cycle of CPX-351 for remission induction.","id":"OG000","title":"CPX-351 (Vyxeos)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Adverse events will be monitored from the time of second course of therapy until the completion of the second course of therapy.","title":"Tolerability Success Rate (TSR) for Patients Completing the Second Course of Chemotherapy","type":"PRIMARY","unitOfMeasure":"Participants"}